Status:
NOT_YET_RECRUITING
A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung Cancer
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Conditions:
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this observational study is to evaluate the safety and efficacy of Adebrelimab Injection in extensive-stage small cell lung cancer (ES-SCLC) under real-world conditions. Specifically, t...
Detailed Description
This trial is a multicenter, non-interventional real-world study aimed at evaluating the safety and efficacy of Adebrelimab in the treatment of extensive-stage small cell lung cancer (ES-SCLC). The st...
Eligibility Criteria
Inclusion
- Patients must meet all of the following criteria to be eligible for inclusion in this study:
- Voluntarily sign the informed consent form and agree to participate in the study.
- Histopathologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
- Age ≥ 18 years.
- Determined by the investigator to be eligible for Adebrelimab treatment.
Exclusion
- Patients with any of the following conditions are not eligible for inclusion in this study:
- Evidence of being a pregnant or lactating female.
- Currently receiving treatment as part of a blinded study protocol.
- Any other condition that the investigator deems unsuitable for inclusion in the study.
Key Trial Info
Start Date :
August 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT06530797
Start Date
August 1 2024
End Date
September 1 2026
Last Update
July 31 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.